PT-141 Dosage Guide: How Much to Take, When, and How

Reviewed by the CoreSup Research Team · Based on FDA-approved Vyleesi label, RECONNECT Phase 3 trial data, and peer-reviewed pharmacokinetic studies · Updated March 2026

Dosage is where most PT-141 users go wrong. The compound has a narrow dose range where efficacy is high and side effects are manageable — drift too low and you get nothing; push too high and nausea becomes the dominant experience. Getting the protocol right is the difference between a compound that works and one that gets shelved after two uses.

The good news: PT-141 (bremelanotide) went through a full FDA approval process, which means there's actual clinical dose-finding data. The RECONNECT Phase 3 trials, which enrolled 1,247 premenopausal women across two 24-week randomised controlled studies, established the 1.75 mg subcutaneous dose as the optimal balance of efficacy and tolerability (PMC6819021). That's a much more reliable foundation than most research peptides ever get.

This guide covers the correct dose, timing, reconstitution method, cycle frequency, sex-specific considerations, and practical strategies to minimise the side effect most people want to avoid — nausea. It's based on clinical data, not anecdote.

TL;DR: The FDA-approved PT-141 dose is 1.75 mg subcutaneous injection, administered at least 45 minutes before activity. First-time users should start at 1–1.25 mg to assess nausea tolerance. Maximum frequency is once per 24 hours, up to 8 uses per month. Effects last 6–12 hours. Reconstitute lyophilised powder with bacteriostatic water at 2.5 mg/mL concentration for easy dosing. Store refrigerated at 2–8°C after reconstitution.

Sourcing PT-141 in UAE? Browse the peptides collection at CoreSup — research-grade bremelanotide with third-party HPLC purity certificates, delivered across Dubai and Abu Dhabi.

What Is the Standard PT-141 Dosage?

The FDA-approved dose for bremelanotide (Vyleesi) is 1.75 mg administered subcutaneously in the abdomen or thigh, at least 45 minutes before anticipated sexual activity. This is the dose validated by the RECONNECT trials and the only dose with formal efficacy and safety data from randomised controlled research. For researchers working outside the FDA-approved female HSDD indication, protocols for men have used a range of 1.25 mg to 2 mg based on available study data (PubMed 14963471).

The 1.75 mg figure isn't arbitrary. Earlier dose-finding studies tested higher doses (up to 10 mg intranasal and multiple mg subcutaneous ranges) and found that above 1.75 mg, side effect frequency increases sharply without proportional increases in efficacy. Below approximately 1 mg, most subjects report insufficient effect. The clinical sweet spot is 1.25–1.75 mg depending on individual tolerance.

Note: These dosage ranges are based on published clinical research and are provided for informational purposes only. PT-141 is not approved for general human use in the UAE. Consult a licensed physician before use.

PT-141 Timing Protocol: When Should You Inject?

PT-141 has well-defined pharmacokinetics from the FDA approval data. Subcutaneous injection produces 100% bioavailability. Peak plasma concentration (T-max) is reached at approximately 1 hour post-injection (DrugBank, bremelanotide). The half-life is approximately 2.7 hours. The FDA label specifies administering at least 45 minutes before anticipated activity.

In practice, most users find injecting 60–90 minutes before their intended window works better than the 45-minute minimum. Why? Because nausea — the most common side effect — peaks within the first 30–60 minutes. If you inject 45 minutes out, the worst of any nausea coincides with the experience you were trying to enjoy. Inject 90 minutes out and the nausea has usually subsided by the time T-max effects are felt.

The Evening Injection Strategy

One of the most effective approaches for nausea-sensitive users is injecting PT-141 3–4 hours before sleep on the night before intended use, rather than same-evening dosing. The compound's 6–12 hour window means it's still fully active the following morning. Nausea — if it occurs — happens during sleep, and users typically wake feeling only the pro-desire effects with none of the early-phase side effects. This strategy is particularly useful for first-time users who want to assess the compound's effect without nausea complicating the experience.

Injection Site

The FDA-approved injection sites are the abdomen (at least 2 inches from the navel) and the outer thigh. Subcutaneous injection means the needle goes into the fatty tissue just under the skin — not into muscle. Use a 29–31 gauge, 4–8 mm insulin needle. Rotate injection sites between uses to prevent localised irritation.

How to Reconstitute PT-141 Powder: Step-by-Step

Most research-grade PT-141 is supplied as a lyophilised (freeze-dried) powder in a sealed vial. This format maximises shelf life before use — typically 2–3 years when stored appropriately. Reconstitution is the process of adding sterile liquid to the powder to create an injectable solution. It sounds technical, but it takes about two minutes once you've done it once.

1. Swab both vial tops with an alcohol wipe and allow to air dry for 30 seconds.
2. Draw 1–2 mL of bacteriostatic water into your larger syringe. For a 5 mg vial, adding 2 mL gives a clean concentration of 2.5 mg/mL — easy to dose with insulin syringes.
3. Inject water slowly down the vial wall — do not aim the stream directly onto the powder. You're trying to dissolve it gently, not agitate it.
4. Swirl gently until the powder fully dissolves. Do not shake. Most PT-141 powder dissolves quickly into a clear solution.
5. Label the vial with the reconstitution date and store refrigerated at 2–8°C. Use within 28 days.

Concentration and Dosing Maths

"Units" refers to insulin syringe markings where 100 units = 1 mL. A standard U-100 insulin syringe is the most accurate tool for measuring these volumes.

How Often Can You Use PT-141? Frequency and Cycle Guidelines

The FDA label for Vyleesi specifies a maximum of one dose per 24 hours and no more than 8 doses per month. These limits aren't arbitrary — they come from the RECONNECT trial safety data and are designed to prevent receptor desensitisation and manage cumulative side effect burden. Exceeding these frequencies doesn't produce linearly better results and increases the likelihood of nausea becoming a persistent issue rather than a transient one.

For most research applications, frequency of 1–4 uses per month is most common. This aligns with the intended use case — PT-141 is an as-needed compound, not a daily supplement. It doesn't build baseline efficacy through consistent use the way some other compounds do. Each use is independent. The 8-per-month ceiling is a safety boundary, not a target.

Does PT-141 Lose Effectiveness Over Time?

Some users report reduced effects after extended use, which is consistent with MC4R receptor downregulation — a known phenomenon with agonist compounds. The practical mitigation is the frequency limit: using PT-141 infrequently (1–4 times per month) rather than at maximum frequency gives receptors time to restore sensitivity between doses. No published data specifically quantifies the receptor recovery timeline for PT-141, but the 24-hour minimum between uses suggests the clinical team anticipated this dynamic.

There's an important practical corollary here: users who "test" PT-141 repeatedly over consecutive days to verify it's working may inadvertently desensitise their MC4R response and conclude the compound is ineffective — when the real issue is use pattern, not compound quality. For UAE researchers evaluating PT-141 for the first time, waiting at least 3–5 days between initial test doses gives a clearer picture of baseline response.

Managing Side Effects Through Dosage Strategy

The most common reason people abandon PT-141 is nausea — which affects approximately 40% of users in the RECONNECT trials. But nausea is highly dose-dependent and timing-dependent, which means it's largely controllable with the right approach. Side effect management through dosage strategy is genuinely effective with this compound in a way that's less true of other peptides.

Titration Protocol (For Nausea-Sensitive Users)

Rather than starting at the full 1.75 mg, titrate upward over 3–4 uses:

• Use 1: 0.75–1.0 mg — assess baseline nausea response
• Use 2: 1.0–1.25 mg — if nausea was mild or absent at use 1
• Use 3: 1.5 mg — if tolerating well
• Use 4+: 1.75 mg (full dose) — once tolerance is established

Many users find that after 3–4 uses, nausea diminishes substantially even at the full dose. This aligns with anecdotal reports and is plausible mechanistically — MC1R, the receptor most implicated in PT-141-related nausea, may show some degree of desensitisation to the nausea-inducing effect faster than MC4R shows desensitisation to the pro-desire effect.

Other Side Effect Strategies

• Hydrate before injection: 500 mL of water 30 minutes prior reduces flushing and headache frequency.
• Avoid alcohol: Concurrent alcohol use increases nausea and flushing — skip it on PT-141 days.
• Light meal beforehand: A small, low-fat meal 1–2 hours before reduces nausea compared to injecting completely fasted.
• Ginger supplementation: 250–500 mg ginger capsules taken with injection has a modest evidence base for reducing nausea from multiple causes; anecdotally reported to help with PT-141 specifically.

For a full breakdown of PT-141's side effect profile and clinical trial data, see the dedicated PT-141 side effects guide. For context on how this compound works mechanistically, read the PT-141 complete guide.

Frequently Asked Questions About PT-141 Dosage

Shop Featured Products

PT-141 Spray 10 mg

Buy Now

PT-141 10 mg

Buy Now